Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Khiron Life Sciences Corp.
  6. News
  7. Summary
    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP.

(KHRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Khiron Life Sciences : Opens First Zerenia™ Clinic in Peru, Prescribing High and Low THC Medical Cannabis Products to Patients

06/10/2021 | 09:01am EDT
  • Company launches first Zerenia™ medical cannabis clinic outside of Colombia, exporting proven clinic model via strategic partnership with Lima-based Clinica Montesur
  • Clinica Montesur is a specialized medical clinic with over 90 doctors covering 19 specialties and 11,000 patient transactions annually; its clinic is centrally located in Lima, Peru, a city of 10 million people or a third of the country's total population
  • Partnership combines Khiron's unique medical cannabis expertise, including the Company's real-world evidence, medical education, best practices and systems, with Clinica Montesur's patient base, clinical infrastructure and medical staff
  • In Q1 2021, Khiron's medical cannabis sales in Peru increased by over 175% compared to total sales in 2020
  • Zerenia™ is the category leader in medical cannabis sales in Colombia, with over 20,000 filled prescriptions and over 8,000 individual patients to date, 50% patient retention, and average 90% gross margins
  • The new Zerenia location brings Khiron's total clinic count to 11 across Latin America

TORONTO, June 10, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announces the launch of its first ZereniaTM clinic outside of Colombia, in Lima, Peru. Following the success of the Company's clinic strategy in Colombia, the new clinic has been established as a strategic partnership between Khiron and Clinica Montesur, a specialized medical provider in Lima with over 90 physicians and more than 11,000 patient transactions annually.

Khiron launches first Zerenia medical cannabis clinic, via a strategic partnership with Lima-based Clinica Montesur

Alvaro Torres, CEO and Director comments, "I am pleased to announce the first expansion of our Zerenia brand beyond Colombia. Knowing that prescription rates at our Zerenia clinics are 14 times higher than those of our external clinic partners, we are excited to bring a proven marketing, sales, and distribution model to a market of over ten million people. To date, our Zerenia clinics have played a vital role in not only introducing patients to Khiron products, but also in developing an exceptional patient experience and growing base of returning patients. As we continue to develop our unique, service-oriented platform, we are proud to introduce  Zerenia to the Peruvian market, where initial reception to our products has been strong since sales began late last year."

Khiron Peru Zerenia Clinic (CNW Group/Khiron Life Sciences Corp.)

With over 30 years of experience in Peru, Clinica Montesur is dedicated to high quality care across 19 areas of specialization, including oncology, dermatology, ophthalmology, and psychology. As part of the strategic partnership, Clinica Montesur will provide clinic infrastructure, including its medical facility, clinic permits, systems, and medical staff, among others. The partnership will leverage Khiron's unique ZereniaTM medical cannabis model, including the Company's medical cannabis education platform, real-world evidence, and standard operating procedures. Patients of the clinic will be able to fill prescriptions for High THC and Low THC (CBD) medical cannabis at ten Farmacia Universal S.A.C. locations throughout Lima, as previously announced by the Company.  

Khiron Peru Zerenia Clinic (CNW Group/Khiron Life Sciences Corp.)

Khiron Peru Zerenia Clinic (CNW Group/Khiron Life Sciences Corp.)

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

© Canada Newswire, source Canada Newswire English

All news about KHIRON LIFE SCIENCES CORP.
07/29KHIRON LIFE SCIENCES : Welcomes Dr. Eduardo Faveret as Medical Director for Braz..
PR
07/26KHIRON LIFE SCIENCES : Up 8.8% as Colombia Expands Medical Marijuana Program and..
MT
07/08KHIRON LIFE SCIENCES : Closes C$12.35 Million Private Placement of Share Units
MT
07/08KHIRON LIFE SCIENCES : Closes $12.3 Million Equity Financing
AQ
07/06UPDATE : Khiron Drops Near 15% as Details Proposed Offering of Securities
MT
07/06KHIRON LIFE SCIENCES : Announces Terms of Overnight Marketed Offering
AQ
07/06KHIRON LIFE SCIENCES : Details Proposed Offering of Securities
MT
07/06Khiron Life to Seek Acquisitions
CI
07/05KHIRON LIFE SCIENCES : Announces Proposed Offering of Securities
AQ
07/02KHIRON LIFE SCIENCES : Announces Results of 2021 Annual General Meeting
PR
More news
Financials
Sales 2021 15,3 M 12,3 M 12,3 M
Net income 2021 -22,2 M -17,8 M -17,8 M
Net cash 2021 11,0 M 8,84 M 8,84 M
P/E ratio 2021 -1,55x
Yield 2021 -
Capitalization 55,5 M 44,6 M 44,6 M
EV / Sales 2021 2,91x
EV / Sales 2022 0,99x
Nbr of Employees -
Free-Float 94,7%
Chart KHIRON LIFE SCIENCES CORP.
Duration : Period :
Khiron Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KHIRON LIFE SCIENCES CORP.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,31 CAD
Average target price 0,95 CAD
Spread / Average Target 206%
EPS Revisions
Managers and Directors
Álvaro F. Torres Chief Executive Officer & Director
Joel Friedman Chief Financial Officer
Chris Naprawa Chairman
Jairo Espinoza Vice President-Medical Affairs
Manuel Buendia Vice President-Operations
Sector and Competitors